Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study
R. Bissonnette; T. Luger; D. Thaçi; D. Toth; I. Messina; R. You; A. Guana; T. Fox; C. Papavassilis; I. Gilloteau; U. Mrowietz
Author Information: Innovaderm Research Inc
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.